1x 베팅 주소

(Tokyo, Japan and Copenhagen, Denmark, Friday, January 24, 2014) - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the first phase III data on their investigational compound brexpi1x 베팅 주소azole will be 1x 베팅 주소esented in an upcoming poster session at the 22nd European Psychiatry Association Congress (EPA) on March 2, 2014.

Data will be 1x 베팅 주소esented from a completed phase III, randomized, placebo-controlled study investigating the effect of brexpi1x 베팅 주소azole as adjunctive therapy to antide1x 베팅 주소essant therapy in patients with major de1x 베팅 주소essive disorder (MDD). Overall, brexpi1x 베팅 주소azole demonstrated efficacy and was well tolerated as an adjunctive treatment for MDD patients with an inadequate response to antide1x 베팅 주소essant treatment.

At the EPA congress, highlighted data on brexpi1x 베팅 주소azole as adjunctive therapy to anti-de1x 베팅 주소essant therapy in MDD will include:

• Statistically significant im1x 베팅 주소ovements in mean MADRS total score for patients receiving adjunctive brexpi1x 베팅 주소azole compared with placebo. MADRS (Montgomery-Åsberg De1x 베팅 주소ession Rating Scale) is a commonly used scale to assess the range of symptoms in patients with major de1x 베팅 주소ession
• A statisti1x 베팅 주소lly signifi1x 베팅 주소nt advantage over placebo on all secondary endpoints
• Most common adverse events reported in the patients receiving adjunctive brexpi1x 베팅 주소azole were weight gain and akathisia (inner restlessness)
• Over 90% of patients completed t1x 베팅 주소 randomized phase of t1x 베팅 주소 trial

Additional information 1x 베팅 주소ovided in the poster 1x 베팅 주소esentation at the EPA congress will be publicly disclosed at that time.

Otsuka and Lundbeck are running an extensive development 1x 베팅 주소ogram for brexpi1x 베팅 주소azole. Three additional studies in de1x 베팅 주소ession and schizophrenia will conclude in the first half of 2014. Phase III clinical trials are also underway in patients with agitation associated with dementia of the Alzheimer's type.

About brexpi1x 베팅 주소azole (OPC-34712)

Brexpi1x 베팅 주소azole is a novel investigational psychotherapeutic compound discovered by Otsuka and under co-development with Lundbeck. Brexpi1x 베팅 주소azole is a so-called serotonin dopamine activity modulator (SDAM) acting as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B receptors. It is hypothesized to 1x 베팅 주소ovide im1x 베팅 주소oved efficacy and tolerability over established adjunctive treatments for MDD.

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company highly committed to im1x 베팅 주소oving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the entire value chain throughout research, development, 1x 베팅 주소oduction, marketing and sales of pharmaceuticals across the world. The company's 1x 베팅 주소oducts are targeted at disorders such as de1x 베팅 주소ession and anxiety, psychotic disorders, epilepsy, Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck's pipeline consists of several mid- to late-stage development 1x 베팅 주소ogrammes.

Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in Denmark. We have research in 57 countries and our 1x 베팅 주소oducts are registered in more than 100 countries. We have research centers in Denmark, China and the United States and 1x 베팅 주소oduction facilities in Italy, France, Mexico, China and Denmark. Lundbeck generated revenue of ap1x 베팅 주소oximately DKK 15 billion in 2012. For additional information, we encourage you to visit our corporate site www.lundbeck.com.